Brief: Celyad Says Preliminary Data For Cycle-1 Trial Anticipated During Second Half 2020

Celyad Oncology SA

10/12/2019 01:25

Dec 9 (Reuters) - Celyad SA  CYAD.BR :
    * CELYAD PRESENTS UPDATE ON R/R AML AND MDS PROGRAM AT 61ST
ASH
ANNUAL MEETING
    * CELYAD SA - CYAD-01 WITHOUT PRECONDITIONING CHEMOTHERAPY
WAS
GENERALLY REPORTED TO BE WELL-TOLERATED
    * CELYAD SA - PLANS TO PROGRESS TO EXPANSION SEGMENT OF
THINK
TRIAL TO FURTHER EVALUATE CYAD-01 PRODUCED WITH OPTIMAB
MANUFACTURING PROCESS
    * CELYAD SA - PRELIMINARY RESULTS FROM R/R AML & MDS PROGRAM
USING
OPTIMAB MANUFACTURING PROCESS ARE EXPECTED BY END OF H1 2020
    * CELYAD SA - ENROLLMENT IN CYCLE-1 TRIAL IS EXPECTED TO
BEGIN IN
EARLY 2020
    * CELYAD SA - PRELIMINARY DATA FOR CYCLE-1 TRIAL ANTICIPATED
DURING SECOND HALF 2020

Source text for Eikon:  ID:nGNX2T6Zw 
Further company coverage:  CYAD.BR 

 ((Reuters Messaging: Reuters.Briefs@thomsonreuters.com))